TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02397122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin
Description: autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: connective tissue graft was harvested from the palatal region of each patient by single incision method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: connective tissue graft was harvested from the palatal region of each patient by single incision method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap
Description: buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
Study: NCT04767594

Intervention type: DRUG
Intervention: Palbociclib + endocrine therapy
Description: Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
Study: NCT02675621

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phenolic Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic Beverage
Study: NCT01703247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglionated plexi ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear Lesion Ablation
Study: NCT03994133

Intervention type: OTHER
Intervention: Measurement of the hydration state by bio-impedance spectroscopy
Description: * The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~* The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~* The measurement will be done in pre-dialytic
Study: NCT04028895

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dosage of IRAP during OGTT
Description: Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
Study: NCT02107859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered per dose and schedule specified in the arm.
Study: NCT01985607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new extensively hydrolysed formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolysed formula
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Study: NCT00797979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skull Grip bone fixation
Description: Skull Grip bone fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sutures
Description: Standard skull bon flap fixation, sutures
Study: NCT02877030

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game
Description: The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
Study: NCT00817999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Participants received grapefruit juice during 1 of the 2 periods.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Participants received grapefruit juice during 1 of the 2 periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Study: NCT00777907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Description: 1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coil embolization
Description: Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
Study: NCT00431184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine
Description: see arms description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine
Description: see arms description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: see arms description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: see arms description
Study: NCT04382703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation Exercise
Description: The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will .........................................~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Given a questionnaire minus the self affirming exercise
Study: NCT01621880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
Study: NCT00714376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 iv every 3 weeks for 8 cycles
Study: NCT01337986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine/Placebo
Description: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Study: NCT01337986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/Dalfampridine
Description: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
Study: NCT02081625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Description: NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks
Study: NCT04077957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (50mg per week, for 4 weeks)
Description: Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (50mg per week, for 2 weeks)
Description: Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (50mg per week)
Description: Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
Study: NCT00632957

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty acid (with SRP or OHI)
Description: 1000mg capsules three times daily, duration 28 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn/soybean oil capsules 1g/three times daily
Study: NCT01817374

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2D US grayscale plus quantitative VCEUS
Description: This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
Study: NCT04078737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Aspirin
Description: Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Aspirin
Description: Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day
Study: NCT00106184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1
Study: NCT02313909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg, once daily, orally, tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: 100 mg, once daily, orally, tablet
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Study: NCT02313909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rivaroxaban-Placebo
Description: Matching placebo, once daily, orally, tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin-Placebo
Description: Matching placebo, once daily, orally, tablet
Study: NCT03258424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: PTI-428 or placebo will be given QD for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PTI-428 or placebo will be given QD for 14 days.
Study: NCT01583686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study: NCT01784133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omiganan
Study: NCT02871960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic and Laparoscopic Colectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic and Laparoscopic Colectomy
Study: NCT03659604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'SmartLife' with tailored feedback
Description: 'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'SmartLife' without tailored feedback
Description: 'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No game
Description: Passive control: School classes will be asked to continue their daily life as usual.
Study: NCT01971164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Subjects will receive JTZ-951 or Placebo
Study: NCT01784133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02289768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/salicylic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT03709082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75mg
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral Adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral Adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral Adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral Adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 100mg
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral Administration
Study: NCT03265899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
Study: NCT01001169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)
Description: Two intramuscular injections
Study: NCT00124020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day IV for up to 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
Study: NCT00555256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib and rapamycin (Drug will be held)
Description: Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
Study: NCT00544115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate